Glaukos (GKOS)
(Delayed Data from NYSE)
$94.29 USD
+1.60 (1.73%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $94.29 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Company Summary
Headquartered in San Clemente, CA, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. Glaukos is focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to treat glaucoma.
Glaukos developed Micro Invasive Glaucoma Surgery (MIGS) to serve as an alternative to the traditional glaucoma treatment and management paradigms. The company’s iStent platform is the first MIGS device in the United States. In 2018, Glaukos launched the next-generation iStent inject device.
The company's product pipeline includes iStent Infinite trabecular micro-bypass system, ...
Company Summary
Headquartered in San Clemente, CA, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. Glaukos is focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to treat glaucoma.
Glaukos developed Micro Invasive Glaucoma Surgery (MIGS) to serve as an alternative to the traditional glaucoma treatment and management paradigms. The company’s iStent platform is the first MIGS device in the United States. In 2018, Glaukos launched the next-generation iStent inject device.
The company's product pipeline includes iStent Infinite trabecular micro-bypass system, iStent Supra suprachoroidal micro-bypass stent, iStent SA trabecular micro-bypass system and iDose.
Glaukos markets its products through direct sales force in the United States and other 16 countries. It has distribution partners in Europe, the Asia Pacific, Latin America, and internationally.
The company currently has 13 publicly-disclosed programs and another 10 yet-to-be-disclosed development programs underway. A number of these pipeline programs are in active pivotal clinical trials.
Full-Year Results at a Glance
In 2023, Glaukos’ net revenues gained 11.3% on a year-over-year basis to $314.7 million. For the full-year 2023, the company reported a loss of $2.27 per share. It had delivered loss per share of $2.18 in 2022..
General Information
Glaukos Corporation
1 GLAUKOS WAY
ALISO VIEJO, CA 92656
Phone: 949-367-9600
Fax: 949-367-9984
Email: investors@glaukos.com
Industry | Medical - Instruments |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 12/31/2023 |
Exp Earnings Date | 5/1/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.59 |
Current Year EPS Consensus Estimate | -2.18 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 5/1/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 92.69 |
52 Week High | 97.24 |
52 Week Low | 45.38 |
Beta | 1.08 |
20 Day Moving Average | 504,158.41 |
Target Price Consensus | 104.17 |
4 Week | 2.94 |
12 Week | 21.32 |
YTD | 16.61 |
4 Week | -0.56 |
12 Week | 8.75 |
YTD | 5.97 |
Shares Outstanding (millions) | 49.47 |
Market Capitalization (millions) | 4,585.41 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | -18.87% |
vs. Previous Quarter | -26.00% |
vs. Previous Year | 15.64% |
vs. Previous Quarter | 5.53% |
Price/Book | 9.80 |
Price/Cash Flow | NA |
Price / Sales | 14.57 |
12/31/23 | -22.67 |
9/30/23 | -20.82 |
6/30/23 | -19.53 |
12/31/23 | -11.50 |
9/30/23 | -10.76 |
6/30/23 | -10.29 |
12/31/23 | 5.34 |
9/30/23 | 5.95 |
6/30/23 | 6.28 |
12/31/23 | 4.78 |
9/30/23 | 5.36 |
6/30/23 | 5.66 |
12/31/23 | -34.87 |
9/30/23 | -34.37 |
6/30/23 | -34.16 |
12/31/23 | -42.79 |
9/30/23 | -42.61 |
6/30/23 | -42.61 |
12/31/23 | -42.49 |
9/30/23 | -42.22 |
6/30/23 | -42.15 |
12/31/23 | 9.46 |
9/30/23 | 9.79 |
6/30/23 | 10.14 |
12/31/23 | 1.87 |
9/30/23 | 1.88 |
6/30/23 | 1.90 |
12/31/23 | 0.77 |
9/30/23 | 0.74 |
6/30/23 | 0.72 |
12/31/23 | 43.35 |
9/30/23 | 42.51 |
6/30/23 | 41.94 |